Ultragenyx Pharmaceutical Inc.
RARE
Jodie situation report
Ultragenyx Pharmaceutical Inc.'s move is being confirmed by its market group.
No new filing conclusion is available. 23 of 24 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 5 directly disclosed connections are confirming.
- At least 16 of 24 members remain active in the next snapshot.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as XNCR begins moving with the group.
Invalidation: The live read weakens if participation falls to 8 of 24 members or fewer.
Who this business touches
The relationships behind RARE
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
REGNRegeneron Pharmaceuticals, Inc.partnerMay 6, 2026 ▾
“If we, our collaborators, such as KKC or Regeneron, or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA or other applicable regulatory authority can impose regulatory sanctions including, among other things, warning or unti…”
MREOFiling-linked namepartnerMay 6, 2026 ▾
“Mereo In December 2020, the Company entered into a License and Collaboration Agreement with Mereo to collaborate on the development of setrusumab.”
Depended on by
REGNRegeneron Pharmaceuticals, Inc.partnerApr 29, 2026 ▾
“Aflibercept 8 mg is known as EYLEA HD in the United States and EYLEA 8 mg in other countries.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 8 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
RARE is currently a Follower in the organic co-movement group Rare Disease Biotech. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.